GLONGHUI, April 7 | CICC released a report saying that Zhongsheng Pharmaceutical's continued business performance last year was in line with expectations. Although revenue from the oncology business declined, revenue from other businesses increased by units. At the same time, the company entered an innovative harvest period. The company expects innovative products to account for 43% and 47% of revenue this year and next, respectively. CICC said that due to the divestment of non-core assets by Zhongsheng Pharmaceuticals, the adjusted earnings forecast per share was lowered by 14% to $0.15 for this year, the forecast for next year was 0.17 yuan, and the target price was lowered 7% to HK$4.2, maintaining the “outperforming industry” rating.